Leiderdorp, Netherlands

Erwin V Achthoven

This inventor holds 1 USPTO granted patent. Top assignee: Hadasit Medical Research Services and Development Ltd.. Active years: 2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Erwin V Achthoven. Retrieved from https://idiyas.com/inventor/erwin-v-achthoven-42tah2uu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Erwin V Achthoven: Innovator in Pharmaceutical Formulations

Introduction

Erwin V Achthoven is a notable inventor based in Leiderdorp, Netherlands. He has made significant contributions to the field of pharmaceuticals, particularly in the formulation of medications. His work focuses on enhancing the bioavailability and dissolution rates of important drugs.

Latest Patents

Achthoven holds a patent for improved formulations of 6-mercaptopurine. This invention provides formulations that exhibit better bioavailability and faster dissolution compared to previous versions. His innovative approach has the potential to enhance the effectiveness of this critical medication.

Career Highlights

Erwin V Achthoven is associated with Hadasit Medical Research Services and Development Ltd. His role in this organization allows him to contribute to cutting-edge research and development in the medical field. His expertise in pharmaceutical formulations has positioned him as a valuable asset in the industry.

Collaborations

Achthoven has worked alongside notable colleagues such as Ruud Smit and Moshe Flashner-Barak. Their collaborative efforts have further advanced the research and development of pharmaceutical innovations.

Conclusion

Erwin V Achthoven's contributions to pharmaceutical formulations, particularly through his patent on 6-mercaptopurine, highlight his role as an innovator in the field. His work continues to impact the effectiveness of important medications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…